Uterine atony

Uterine atony
Video explanation of postpartum bleeding
SpecialtyObstetrics
SymptomsPostpartum bleeding[1]
ComplicationsAnemia, iron deficiency[1]
Usual onsetPost delivery[1]
Risk factorsProlonged labor, precipitous labor, uterine distension (twins, polyhydramnios, large for gestational age), fibroids, BMI > 40, chorioamnionitis[1]
Diagnostic methodExamination[1]
Differential diagnosisRetained placenta, lacerations, uterine inversion[1]
PreventionOxytocin[1]
TreatmentUterine massage, medications, packing, surgery[1]
MedicationOxytocin, methylergometrine, carboprost, misoprostol, prostaglandin E2[1]
Frequency2.5% of deliveries[1]

Uterine atony is the failure of the uterus to contract adequately following delivery.[1] Symptoms can include post partum bleeding, of which it is the causes in more than 75% of cases.[1] Complications may include anemia and iron deficiency.[1]

Risk factors include prolonged labor, precipitous labor, uterine distension (twins, polyhydramnios, large for gestational age), fibroids, BMI > 40, and chorioamnionitis.[1] Contraction of the muscles of the uterus is required to close the blood vessels that supply were the placenta attaches after its delivery.[1] Diagnosis is by feeling the uterus following delivery.[1] Other conditions that may present similarly include retained placenta, uterine inversion, and lacerations associated with delivery.[1]

Blood products should be ready for us in those at high risk.[1] Oxytocin may also be given to try to prevent its occurrence.[1] Treatment may include uterine massage, medications, uterus packing, or surgery.[1] Medications that may be used include oxytocin, methylergometrine, carboprost, misoprostol, or prostaglandin E2.[1] Uterine atony occurs in 2.5% of deliveries in the United States.[1] Globally postpartum bleeding is a top 5 causes of maternal death.[2]

Signs and symptoms

Symptoms of uterine atony can include post partum bleeding.

Complications

PPH can cause a multitude of complications including:[2][3]

In low‐income countries there are several other factors that play a role in PPH risk. Poor nutritional status, lack of healthcare access, and limited blood product supply are additional factors that increase morbidity and mortality.[4]

Postpartum anemia is common after an episode of uterine atony and postpartum hemorrhage.[1] Severe anemia due to PPH may require red cell transfusions, depending on the severity of anemia and the degree of symptomatology attributable to anemia. A common practice is to offer a transfusion to symptomatic women with a hemoglobin value less than 7 g/dL. In most cases of uterine atony-related postpartum hemorrhage, the amount of iron lost is not fully replaced by the transfused blood. Oral iron should thus be also considered. Parenteral iron therapy is an option as it accelerated recovery. Most women with mild to moderate anemia, however, resolve the anemia sufficiently rapidly with oral iron alone and do not need parenteral iron.[1][2]

Risk factors

There are many risk factors for uterine atony and several are due to the type of labor a mother experiences such as prolonged labor, labor lasting less than 3 hours, uterine inversion, the use of magnesium sulfate infusions, and extended use of oxytocin. Uterine distention caused by things like more than one fetus present, polyhydramnios, fetal macrosomia, uterine fibroids, chorioamnionitis can also lead to decreased uterine function and atony. Retained placental tissue or placental disorders, such as an adherent placenta, placenta previa, and abruption placentae increase the mother's risk of PPH. Body mass index (BMI) above 40 and coagulopathies are known risk factors.[1][5][2][6]

Magnesium sulfate is used often in people with preeclampsia and eclampsia, can inadvertently inhibit uterine contractions. In addition, preeclampsia can lead to blood disorders such as thrombocytopenia, platelet abnormalities, and disseminated intravascular coagulation.[7]. Cesarean delivery, especially after prolonged labor, may cause the muscles of the uterus to become tired and stop contracting or contraction can be inhibited at the surgical site.[2]

Pathophysiology

The uterus is composed of a interconnected muscle fibers known as the myometrium. The blood vessels that provide the blood supply to the placenta pass through this muscle.[8] After labor it is the contraction of these muscles that physically squeeze the blood vessels so that hemostasis can occur after the delivery of the fetus and the placenta.[1] Local hemostatic factors like tissue factor type-1 plasminogen activator inhibitor and platelets and clotting factors aid in stopping the blood flow.[1][8]

This physiological contraction does not occur if the myometrium becomes atonic. Oxytocin is released continuously during labor to stimulate uterine muscle contraction so the that the fetus can be delivered and it is continued to be released after delivery to stop blood flow.[9] If the oxytocin receptors become desensitized and no longer respond to the hormone then the uterus does not contract.[10] The uterus can also be structurally damaged or distended to prevent contraction. Therefore, as placenta is delivered arteries are damaged and without the muscle contractions hemostasis cannot be reached.[1]

Blood loss is an expected part of labor and less than 500 mL is considered normal.[11] Generally, primary PPH is classified as being more than 500 mL of blood lost in the first 24 hours following delivery.[2] Those who have a caesarean section typically have more blood loss than a vaginal birth; so 1000 mL is commonly used to determine excessive blood loss. It is easy to underestimate maternal blood loss because the primary method of assessment is visual observation.[12][13]

Diagnosis

Identifying risk factors early in the pregnancy is essential in managing uterine atony and PPH.[14] This allows for planning and organizing the necessary resources including staff, medicines, assistive devices, and the proper blood products. The delivery plan should also be cognizant of the ability of the hospital or facility to provide an appropriate level of care if any complications occur.[1]

Most diagnosis of uterine atony are made during the physical exam directly upon completion of the delivery. Diffuse uterine atony is typically diagnosed by patient observation rather than blood loss. The uterus can be directly palpated or observed indirectly using a bimanual examination post delivery. An atonic uterus can feel soft, "boggy" and/or enlarged.[2] Bleeding from the cervical os is also common. If the atony is localized to one area of the uterus, the upper, fundal region may be still be squeezing while the lower uterine segment is non functional. This can be difficult to see with a cursory abdominal examination and easily overlooked. Therefore, a comprehensive vaginal, abdominal, and rectal examination should be performed. The physical examination may include ultrasound imaging for rapid visualization of the uterus and other causes of bleeding.[1] Expulsion of gestational products such as the placenta and rapid identification of obstetric lacerations, helps exclude other causes of PPH.[1] Laboratory tests can be drawn if coagulopathies are suspected.

Prevention

Postpartum bleeding risks[3]
Medium risk High risk
Prior uterine surgery Placenta previa
Multiple gestation Placenta accrete
Grand multi-parity Active bleeding
Prior PPH ≥ 2 medium risk factors
Large fibroids Platelets < 70,000
Macrosomia Known coagulopathy
BMI >40
Anemia
Chorioamnionitis
Prolonged 2nd stage labor
Oxytocin longer than 24 hrs
Magnesium sulfate administration

Before delivery all people should be screened for risk factors and then assigned a postpartum bleeding risk stratification based on the American College of Obstetricians and Gynecologists recommendations. If the woman is at a medium risk, blood should be typed and screened. Those assessed to be high risk should be typed and cross-matched.[1][3]

Active management of the third stage of labor is routinely implemented and is considered the standard for patient care. It can be utilized to reduce the risk of PPH.[15][16] Active management of the third stage includes uterine massage and a IV low dose oxytocin. Whether it is given just before or after the delivery of the placenta is subject to provider preference.[1] It is suggested that using an uterotonic, such as oxytocin, prophylactically will help reduce blood loss and the need for a blood transfusion after delivery.[17]

A uterine massage is performed by placing a hand on the lower abdomen and using repetitive massaging or squeezing movements in attempt to stimulate the uterus. It is theorized, the massaging motion stimulates uterine contraction and may also trigger the release of local prostaglandins to help hemostasis.[18]

Treatment

If uterine atony occurs even after all preventative measures have been taken, medical management should be implemented. Uterine fundal massage and compression should be maintained, while while drugs are administered.[1] An intravenous catheter should also be started to administer fluids, medications, and blood products[19]

Medications

There are several different types of uterotonic drugs that may be given, and the each has their own advantages and disadvantages.[20] Moreover, the use of combination uterotonic therapy is a common practice and might be more effective at controlling bleeding than a single medication. Some combinations might include oxytocin plus misoprostol, oxytocin plus ergometrine, and carbetocin.[21]

Medications used for PPH include the following:[1][2]

  • Oxytocin Stimulation of oxytocin receptors in the uterine muscle leads to contractions.[22] The number of these receptors increases during pregnancy and with labor. There are also more in the fundus than in the lower uterine segment.[23] Oxytocin has a quick onset of action, within a few minutes, but also loses effectiveness quickly because of a short half-life.The medicine is given in a rapid infusion and may cause hypotension. Oxytocin alone is the usually treatment of atony in the US. However, if bleeding is uncontrolled after administration of oxytocin, then a second uterotonic is given. [21]
  • Carbetocin: A synthetic analog of oxytocin, works similarly to oxytocin but the half-life is much longer.[24] It binds to smooth muscle receptors of the uterus, like oxytocin, and has been reported to produce a stable uterine contraction, followed by rhythmic contractions. It is not available in the US but is available in many countries for prevention of uterine atony and hemorrhage.
  • Methylergometrine: This is an ergot alkaloid and has multiple mechanisms of action to induce fast, regular uterine contractions which leads to sustained uterine contraction.[25] It can cause peripheral vasoconstriction and is contraindicated in people with hypertension or pregnancy related hypertension.[26]
  • 15-methyl-PGF2-alpha (Hemabate, Carboprost) Highly effective but it is expensive. It can cause bronchospasm and it should be avoided in asthmatics. May cause diarrhea, fevers, or tachycardia.[27]
  • Misoprostol A synthetic prostaglandin E1 analog oral medication that can stimulate uterine contractions. Misoprostol does not need to be refrigerated because it is heat stable. It is easy to administer compared with oxytocin and ergot alkaloids in low-resource areas where refrigeration and sterile needles are not available.[28] May cause a low-grade fever.
  • Prostaglandin E2 An alternative prostaglandin to misoprostol.[2]

Procedures

An intrauterine balloon catheter is positioned on the center of two sheets of gauze impregnated with tranexamic acid
Device with balloon inflated with sterile water

After the medication is administered, the mother should be closely observed for to confirm the bleeding has stopped. If the bleeding has not stopped or physical exam does not show signs of restored uterine function within 30 minutes of medication administration, immediate invasive interventions are recommended.[29][1][30]

Tamponade techniques include uterine packing (extending into the vagina) with gauze that also has a Foley catheter in place to allow for bladder drainage. It is inexpensive and readily available.[1][17] Balloon tamponade is the suggested method of tamponade in guidelines for management of PPH.[31] A bakri balloon to tamponade (also with vaginal packing) can be used with Foley catheter insertion to facilitate bladder drainage.[1][32] Vacuum-induced uterine tamponade is newer technique that uses low-level vacuum to evacuate blood from the uterine cavity and facilitate uterine contraction.[33]

Surgery

Surgical management techniques include:

  • Compression sutures such as the B-Lynch[1][30]
  • Uterine curettage to remove retained placental products[1][34]
  • Uterine artery ligation, with or without ligation of the tubo-ovarian vessels. [1][35] Ligation of the uterine and utero-ovarian arteries can decrease uterine bleeding by reducing the pressure of arterial blood flow in the uterus. It will not completely control the bleeding but may decrease blood loss while other interventions are being attempted.
  • Hypogastric artery ligation. Bilateral ligation of the internal iliac arteries reduces the pulse pressure of blood flowing to the uterus similar to uterine artery ligation. However, it is not a common procedure because of the degree of difficulty and risks.[36]
  • Hysterectomy

Prognosis

Women with a history of PPH have a 2 to 3 times higher risk of PPH in their following pregnancies.[37][1][38]

Epidemiology

Uterine atony occurs during 1 in 40 births in the United States and is responsible for at least 80% of cases of postpartum hemorrhage.[1][39][6]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Gill P, Patel A, Van Hook JW (2020). "Uterine Atony". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29630290. Archived from the original on 2021-08-27. Retrieved 2020-10-19. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License Archived 2017-10-16 at the Wayback Machine.
  2. 1 2 3 4 5 6 7 8 9 Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z, et al. (Cochrane Pregnancy and Childbirth Group) (February 2014). "Treatment for primary postpartum haemorrhage". The Cochrane Database of Systematic Reviews (2): CD003249. doi:10.1002/14651858.CD003249.pub3. PMC 6483801. PMID 24523225.
  3. 1 2 3 Hussain SA, Guarini CB, Blosser C, Poole AT (December 2019). "Obstetric Hemorrhage Outcomes by Intrapartum Risk Stratification at a Single Tertiary Care Center". Cureus. 11 (12): e6456. doi:10.7759/cureus.6456. PMC 6977573. PMID 32025387. Archived from the original on 2020-10-24. Retrieved 2020-10-20.
  4. ↑ Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF (April 2006). "WHO analysis of causes of maternal death: a systematic review". Lancet. 367 (9516): 1066–1074. doi:10.1016/S0140-6736(06)68397-9. PMID 16581405. S2CID 2190885.
  5. ↑ Breathnach F, Geary M (April 2009). "Uterine atony: definition, prevention, nonsurgical management, and uterine tamponade". Seminars in Perinatology. 33 (2): 82–7. doi:10.1053/j.semperi.2008.12.001. PMID 19324236.
  6. 1 2 Wetta, Luisa A.; Szychowski, Jeff M.; Seals, Samantha; Mancuso, Melissa S.; Biggio, Joseph R.; Tita, Alan T. N. (2013). "Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery". American Journal of Obstetrics and Gynecology. 209 (1): 51.e1–6. doi:10.1016/j.ajog.2013.03.011. ISSN 1097-6868. PMC 3788839. PMID 23507549. Archived from the original on 2021-04-20. Retrieved 2020-10-23.
  7. ↑ Ciobanu, Anca Marina; Colibaba, Simona; Cimpoca, Brandusa; Peltecu, Gheorghe; Panaitescu, Anca Maria (2016). "Thrombocytopenia in Pregnancy". Maedica. 11 (1): 55–60. ISSN 1841-9038. PMC 5394486. PMID 28465752. Archived from the original on 2021-04-20. Retrieved 2020-10-23.
  8. 1 2 Baskett TF (September 2000). "A flux of the reds: evolution of active management of the third stage of labour". Journal of the Royal Society of Medicine. 93 (9): 489–93. doi:10.1177/014107680009300913. PMC 1298111. PMID 11089490. Archived from the original on 2021-08-27. Retrieved 2020-10-19.
  9. ↑ Belghiti, J.; Kayem, G.; Dupont, C.; Rudigoz, R.-C.; Bouvier-Colle, M.-H.; Deneux-Tharaux, C. (2011-12-21). "Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study". BMJ Open. 1 (2): e000514. doi:10.1136/bmjopen-2011-000514. ISSN 2044-6055. PMC 3334825. PMID 22189353. Archived from the original on 2021-08-27. Retrieved 2020-10-23.
  10. ↑ Belghiti, J.; Kayem, G.; Dupont, C.; Rudigoz, R.-C.; Bouvier-Colle, M.-H.; Deneux-Tharaux, C. (2011-12-21). "Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study". BMJ Open. 1 (2): e000514. doi:10.1136/bmjopen-2011-000514. ISSN 2044-6055. PMC 3334825. PMID 22189353. Archived from the original on 2021-08-27. Retrieved 2020-10-23.
  11. ↑ Ripley DL (September 1999). "Uterine emergencies. Atony, inversion, and rupture". Obstetrics and Gynecology Clinics of North America. 26 (3): 419–34, vii. doi:10.1016/S0889-8545(05)70087-5. PMID 10472062. Archived from the original on 2021-08-27. Retrieved 2020-10-19.
  12. ↑ Sloan NL, Durocher J, Aldrich T, Blum J, Winikoff B (June 2010). "What measured blood loss tells us about postpartum bleeding: a systematic review". BJOG. 117 (7): 788–800. doi:10.1111/j.1471-0528.2010.02567.x. PMC 2878601. PMID 20406227.{{cite journal}}: CS1 maint: url-status (link)
  13. ↑ Stafford I, Dildy GA, Clark SL, Belfort MA (November 2008). "Visually estimated and calculated blood loss in vaginal and cesarean delivery". American Journal of Obstetrics and Gynecology. 199 (5): 519.e1–7. doi:10.1016/j.ajog.2008.04.049. PMID 18639209. Archived from the original on 2021-08-27. Retrieved 2020-10-19.
  14. ↑ Bateman BT, Berman MF, Riley LE, Leffert LR (May 2010). "The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries". Anesthesia and Analgesia. 110 (5): 1368–73. doi:10.1213/ANE.0b013e3181d74898. PMID 20237047. S2CID 46459480.
  15. ↑ McDonald S (2007-05-01). "Management of the third stage of labor". Journal of Midwifery & Women's Health. Special Continuing Education Issue on Intrapartum Care. 52 (3): 254–61. doi:10.1016/j.jmwh.2007.02.012. PMID 17467592.
  16. ↑ Anderson, Janice M.; Etches, Duncan (2007-03-15). "Prevention and management of postpartum hemorrhage". American Family Physician. 75 (6): 875–882. ISSN 0002-838X. PMID 17390600. Archived from the original on 2021-04-20. Retrieved 2020-10-23.
  17. 1 2 Begley CM, Gyte GM, Devane D, McGuire W, Weeks A, Biesty LM, et al. (The Cochrane Collaboration) (February 2019). Begley CM (ed.). "Active versus expectant management for women in the third stage of labour". The Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. 2: CD007412. doi:10.1002/14651858.cd007412. PMC 6372362. PMID 30754073.
  18. ↑ "WHO recommendation on the use of uterine massage for the treatment of postpartum haemorrhage | RHL". extranet.who.int. Archived from the original on 2020-10-21. Retrieved 2020-10-20.
  19. ↑ El Senoun GA, Singh M, Mousa HA, Alfirevic Z (November 2011). "Update on the new modalities on the prevention and management of postpartum haemorrhage". Fetal and Maternal Medicine Review. 22 (4): 247–264. doi:10.1017/S0965539511000143. ISSN 0965-5395.
  20. ↑ McDonald S, Abbott JM, Higgins SP, et al. (Cochrane Pregnancy and Childbirth Group) (2004). "Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour". The Cochrane Database of Systematic Reviews (1): CD000201. doi:10.1002/14651858.CD000201.pub2. PMC 6491201. PMID 14973949.
  21. 1 2 Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer, David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp, Özge (2018-04-25). Cochrane Pregnancy and Childbirth Group (ed.). "Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis". Cochrane Database of Systematic Reviews. 4: CD011689. doi:10.1002/14651858.CD011689.pub2. PMC 6494487. PMID 29693726. Archived from the original on 2021-08-27. Retrieved 2020-10-22.
  22. ↑ Dyer, R.A.; van Dyk, D.; Dresner, A. (2010). "The use of uterotonic drugs during caesarean section". International Journal of Obstetric Anesthesia. 19 (3): 313–319. doi:10.1016/j.ijoa.2010.04.011. PMID 20627531. Archived from the original on 2018-07-02. Retrieved 2020-10-22.
  23. ↑ ARIAS, FERNANDO (2000). "Pharmacology of Oxytocin and Prostaglandins". Clinical Obstetrics and Gynecology. 43 (3): 455–468. doi:10.1097/00003081-200009000-00006. ISSN 0009-9201. PMID 10949750. Archived from the original on 2021-08-27. Retrieved 2020-10-22.
  24. ↑ Rath, Werner (2009). "Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin". European Journal of Obstetrics & Gynecology and Reproductive Biology. 147 (1): 15–20. doi:10.1016/j.ejogrb.2009.06.018. PMID 19616358. Archived from the original on 2018-07-03. Retrieved 2020-10-22.
  25. ↑ den Hertog, C.E.C.; de Groot, A.N.J.A.; van Dongen, P.W.J. (2001). "History and use of oxytocics". European Journal of Obstetrics & Gynecology and Reproductive Biology. 94 (1): 8–12. doi:10.1016/S0301-2115(00)00311-0. PMID 11134819. Archived from the original on 2018-06-26. Retrieved 2020-10-22.
  26. ↑ Butwick, Alexander J.; Carvalho, Brendan; Blumenfeld, Yair J.; El-Sayed, Yasser Y.; Nelson, Lorene M.; Bateman, Brian T. (2015). "Second-line uterotonics and the risk of hemorrhage-related morbidity". American Journal of Obstetrics and Gynecology. 212 (5): 642.e1–7. doi:10.1016/j.ajog.2015.01.008. ISSN 1097-6868. PMC 4416982. PMID 25582104. Archived from the original on 2020-10-27. Retrieved 2020-10-23.
  27. ↑ Lamba, Akanksha; Joshi, Godawari; Gupta, Madhulika (2017-02-23). "Role of carboprost in prevention of postpartum hemorrhage". International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 5 (7): 2151–2154. doi:10.18203/2320-1770.ijrcog20162082. ISSN 2320-1789. Archived from the original on 2020-10-28. Retrieved 2020-10-23.
  28. ↑ Alfirevic, Z.; Blum, J.; Walraven, G.; Weeks, A.; Winikoff, B. (2007). "Prevention of postpartum hemorrhage with misoprostol". International Journal of Gynecology & Obstetrics. 99: S198–S201. doi:10.1016/j.ijgo.2007.09.012. PMID 17961574. S2CID 45977576. Archived from the original on 2021-08-27. Retrieved 2020-10-22.
  29. ↑ Songthamwat S, Songthamwat M (2018). "Uterine flexion suture: modified B-Lynch uterine compression suture for the treatment of uterine atony during cesarean section". International Journal of Women's Health. 10: 487–492. doi:10.2147/IJWH.S170460. PMC 6113941. PMID 30197543.
  30. 1 2 Songthamwat S, Songthamwat M (2018-08-24). "Uterine flexion suture: modified B-Lynch uterine compression suture for the treatment of uterine atony during cesarean section". International Journal of Women's Health. 10: 487–492. doi:10.2147/ijwh.s170460. PMC 6113941. PMID 30197543.
  31. ↑ Dahlke, Joshua D.; Mendez-Figueroa, Hector; Maggio, Lindsay; Hauspurg, Alisse K.; Sperling, Jeffrey D.; Chauhan, Suneet P.; Rouse, Dwight J. (2015). "Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines". American Journal of Obstetrics and Gynecology. 213 (1): 76.e1–76.e10. doi:10.1016/j.ajog.2015.02.023. PMID 25731692. Archived from the original on 2020-05-05. Retrieved 2020-10-22.
  32. ↑ Abraham C (2017). "Bakri balloon placement in the successful management of postpartum hemorrhage in a bicornuate uterus: A case report". International Journal of Surgery Case Reports. 31: 218–220. doi:10.1016/j.ijscr.2017.01.055. PMC 5302184. PMID 28189983. Archived from the original on 2018-06-29. Retrieved 2020-10-20.
  33. ↑ Hofmeyr, Gj; Singata‐Madliki, M (2020). "Novel suction tube uterine tamponade for treating intractable postpartum haemorrhage: description of technique and report of three cases". BJOG: An International Journal of Obstetrics & Gynaecology. 127 (10): 1280–1283. doi:10.1111/1471-0528.16169. ISSN 1470-0328. PMID 32043686. S2CID 211079411.
  34. ↑ Porreco, Richard P.; Stettler, Robert W. (2010). "Surgical Remedies for Postpartum Hemorrhage". Clinical Obstetrics and Gynecology. 53 (1): 182–195. doi:10.1097/GRF.0b013e3181cc4139. ISSN 0009-9201. PMID 20142655. S2CID 1501779. Archived from the original on 2021-08-27. Retrieved 2020-10-23.
  35. ↑ Shahin AY, Farghaly TA, Mohamed SA, Shokry M, Abd-El-Aal DE, Youssef MA (March 2010). "Bilateral uterine artery ligation plus B-Lynch procedure for atonic postpartum hemorrhage with placenta accreta". International Journal of Gynaecology and Obstetrics. 108 (3): 187–90. doi:10.1016/j.ijgo.2009.08.035. PMID 19944417. S2CID 9565057. Archived from the original on 2020-10-22. Retrieved 2020-10-20.
  36. ↑ Clark, Steven L.; Phelan, Jeffrey P.; Yeh, Sze-Ya; Bruce, Samuel R.; Paul, Richard H. (1985). "Hypogastric Artery Ligation for Obstetric Hemorrhage". Obstetrics & Gynecology. 66 (3): 353–356. ISSN 0029-7844. PMID 3875064. Archived from the original on 2020-10-26. Retrieved 2020-10-22.
  37. ↑ Oberg, Anna Sara; Hernandez-Diaz, Sonia; Palmsten, Kristin; Almqvist, Catarina; Bateman, Brian T. (2014). "Patterns of recurrence of postpartum hemorrhage in a large population-based cohort". American Journal of Obstetrics and Gynecology. 210 (3): 229.e1–8. doi:10.1016/j.ajog.2013.10.872. ISSN 1097-6868. PMC 3943527. PMID 24351791. Archived from the original on 2021-04-20. Retrieved 2020-10-23.
  38. ↑ Kominiarek MA, Kilpatrick SJ (June 2007). "Postpartum hemorrhage: a recurring pregnancy complication". Seminars in Perinatology. 31 (3): 159–66. doi:10.1053/j.semperi.2007.03.001. PMID 17531897. Archived from the original on 2018-06-11. Retrieved 2020-10-20.
  39. ↑ Abraham C (2017-01-24). "Bakri balloon placement in the successful management of postpartum hemorrhage in a bicornuate uterus: A case report". International Journal of Surgery Case Reports. 31: 218–220. doi:10.1016/j.ijscr.2017.01.055. PMC 5302184. PMID 28189983.
Classification
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.